SPOTLIGHT: Synta gets fast track for cancer therapy


The FDA has granted Synta Pharmaceuticals fast-track status for its lead oncology drug candidate, STA-4783. In a recently completed, Phase IIb clinical trial in patients with Stage IV metastatic malignant melanoma, treatment with STA-4783 plus paclitaxel achieved the primary endpoint of increasing progression-free survival. Synta was a 2004 Fierce 15 company. Release